Differential effects of calmodulin antagonists on phospholipases A2 and C in thrombin-stimulated platelets.
D016718:Arachidonic Acid; D001095:Arachidonic Acids / Q000097:blood; D001792:Blood Platelets / Q000201:enzymology*; D002135:Calcium-Binding Proteins / Q000037:antagonists & inhibitors*; D002147:Calmodulin / Q000037:antagonists & inhibitors*; D002746:Chlorpromazine / Q000494:pharmacology; D003992:Dibucaine / Q000494:pharmacology; D005476:Fluphenazine / Q000494:pharmacology; D006801:Humans; D007700:Kinetics; D010740:Phospholipases / Q000097:blood*; D010741:Phospholipases A / Q000097:blood*; D010743:Phospholipids / Q000097:blood; D010974:Platelet Aggregation / Q000187:drug effects; D011796:Quinacrine / Q000494:pharmacology; D013917:Thrombin / Q000494:pharmacology*; D014268:Trifluoperazine / Q000494:pharmacology*; D010738:Type C Phospholipases / Q000097:blood*
D001095:Arachidonic Acids; D002135:Calcium-Binding Proteins; D002147:Calmodulin; D010743:Phospholipids; D014268:Trifluoperazine; D016718:Arachidonic Acid; D010740:Phospholipases; D010741:Phospholipases A; D010738:Type C Phospholipases; D013917:Thrombin; D011796:Quinacrine; D003992:Dibucaine; D005476:Fluphenazine; D002746:Chlorpromazine